ArticleInternational journal of nanomedicine2016
Development of nanostars as a biocompatible tumor contrast agent: toward in vivo SERS imaging.
Article in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Gold Nanostars as Multifunctional Platforms in Cancer Imaging and Therapy: Toward Radiotheranostic Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Application of Dual-Enhanced Surface-Enhanced Raman Scattering Probe Technology in the Diagnosis of Tumor Cells in Vitro.Molecules (Basel, Switzerland) · 2022Article
- Recent Advances in Metallic Nanoparticle Assemblies for Surface-Enhanced Spectroscopy.International journal of molecular sciences · 2021Review
- Gold Nanostar Spatial Distribution Impacts the Surface-Enhanced Raman Scattering Detection of Uranyl on Amidoximated Polymers.Langmuir : the ACS journal of surfaces and colloids · 2021Article
- Intraoperative Assessment and Photothermal Ablation of the Tumor Margins Using Gold Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Tuning gold nanostar morphology for the SERS detection of uranyl.Journal of Raman spectroscopy : JRS · 2021Article
- Label-Free Iron Oxide Nanoparticles as Multimodal Contrast Agents in Cells Using Multi-Photon and Magnetic Resonance Imaging.International journal of nanomedicine · 2021Article
- Assessment of the Theranostic Potential of Gold Nanostars-A Multimodal Imaging and Photothermal Treatment Study.Nanomaterials (Basel, Switzerland) · 2020Article
- High-sensitivity SERS based sensing on the labeling side of glass slides using low branched gold nanoparticles prepared with surfactant-free synthesis.RSC advances · 2020Article
- Tissue Phantoms for Biomedical Applications in Raman Spectroscopy: A Review.Biomedical engineering and computational biology · 2020Review
- Contrast-enhanced computed tomography combined with Chitosan-FeExperimental and therapeutic medicine · 2018Article
- Combined use of vancomycin-modified Ag-coated magnetic nanoparticles and secondary enhanced nanoparticles for rapid surface-enhanced Raman scattering detection of bacteria.International journal of nanomedicine · 2018Article
- Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.International journal of molecular sciences · 2017Review
- Gold nanoparticles enlighten the future of cancer theranostics.International journal of nanomedicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need for sensitive imaging techniques to detect tumor cells is an important issue in cancer diagnosis and therapy. Surface-enhanced Raman scattering (SERS), realized by chemisorption of compounds suitable for Raman spectroscopy onto gold nanoparticles, is a new method for detecting a tumor. As a proof of concept, we studied the use of biocompatible gold nanostars as sensitive SERS contrast agents targeting an ovarian cancer cell line (SKOV3). Due to a high intracellular uptake of gold nanostars after 6 hours of exposure, they could be detected and located with SERS. Using these nanostars for passive targeting after systemic injection in a xenograft mouse model, a detectable signal was measured in the tumor and liver in vivo. These signals were confirmed by ex vivo SERS measurements and darkfield microscopy. In this study, we established SERS nanostars as a highly sensitive contrast agent for tumor detection, which opens the potential for their use as a theranostic agent against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.